No connection

Search Results

SENS vs TLSI

SENS
Senseonics Holdings, Inc.
BEARISH
Price
$6.77
Market Cap
$283.0M
Sector
Healthcare
AI Confidence
85%
TLSI
TriSalus Life Sciences, Inc.
BEARISH
Price
$4.60
Market Cap
$282.5M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
SENS
--
TLSI
--
Forward P/E
SENS
-2.57
TLSI
-18.4
P/B Ratio
SENS
4.58
TLSI
-6.79
P/S Ratio
SENS
8.03
TLSI
6.26
EV/EBITDA
SENS
-3.44
TLSI
-11.25

Profitability

Gross Margin
SENS
44.71%
TLSI
84.57%
Operating Margin
SENS
-146.78%
TLSI
-24.77%
Profit Margin
SENS
-196.03%
TLSI
-86.88%
ROE
SENS
-168.27%
TLSI
--
ROA
SENS
-37.68%
TLSI
-56.8%

Growth

Revenue Growth
SENS
71.8%
TLSI
59.8%
Earnings Growth
SENS
--
TLSI
--

Financial Health

Debt/Equity
SENS
0.68
TLSI
--
Current Ratio
SENS
4.83
TLSI
2.8
Quick Ratio
SENS
4.37
TLSI
2.35

Dividends

Dividend Yield
SENS
--
TLSI
--
Payout Ratio
SENS
0.0%
TLSI
0.0%

AI Verdict

SENS BEARISH

SENS exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company shows impressive top-line revenue growth of 71.80% and maintains a strong liquidity position (Current Ratio 4.83), these are offset by a devastating profit margin of -196.03% and a consistent track record of missing earnings estimates. The stock is in a long-term bearish trend with a 5-year decline of 81.7%, suggesting that the market is discounting the growth in favor of the unsustainable burn rate.

Strengths
Strong YoY revenue growth of 71.80%
High liquidity with a Current Ratio of 4.83
Positive Gross Margin of 44.71% indicating product viability
Risks
Critical financial health (Piotroski F-Score 1/9)
Severe negative profitability (Profit Margin -196.03%)
Poor earnings track record with 0/4 beats in the last year
TLSI BEARISH

TLSI exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -6.79, indicating negative shareholders' equity. While the company shows strong top-line revenue growth of 59.80% and high gross margins, these are offset by a devastating profit margin of -86.88% and consistent earnings misses. The stark disconnect between the 'Strong Buy' analyst consensus and the bearish insider selling by the CEO and officers suggests a high-risk speculative profile. Overall, the deterministic health indicators signal a high probability of further capital erosion or dilution.

Strengths
Strong YoY revenue growth of 59.80%
High gross margin of 84.57% indicating strong product pricing power
Healthy short-term liquidity with a current ratio of 2.80
Risks
Negative shareholders' equity (P/B of -6.79) indicating insolvency risk
Critical Piotroski F-Score (1/9) signaling fundamental weakness
Extreme negative profit margins (-86.88%)

Compare Another Pair

SENS vs TLSI: Head-to-Head Comparison

This page compares Senseonics Holdings, Inc. (SENS) and TriSalus Life Sciences, Inc. (TLSI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile